NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today reported financial results for the first quarter ended March 31, 2026, and provided a business update across its clinical pipeline...
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today reported financial results for the first quarter ended March 31, 2026, and provided a business update across its clinical pipeline.
Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027
Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027
LAS VEGAS, May 12, 2026 (GLOBE NEWSWIRE) -- TON Strategy Company (“TON Strategy” or the “Company”) (Nasdaq: TONX) , a digital asset treasury company dedicated to holding Toncoin ($TON), today reported financial results for the first quarter ended March 31, 2026 and provided an update on its TON treasury operations.
LAS VEGAS, May 12, 2026 (GLOBE NEWSWIRE) -- TON Strategy Company (“TON Strategy” or the “Company”) (Nasdaq: TONX) , a digital asset treasury company dedicated to holding Toncoin ($TON), today reported financial results for the first quarter ended March 31, 2026 and provided an update on its TON treasury operations.
PRINCETON, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.
PRINCETON, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.
fcafotodigital/iStock via Getty Images Introduction AGNC Investment Corp. ( AGNC ) is a Mortgage REIT that offers numerous preferred stocks for income-seeking investors to choose from. These are normally viewed as riskier than preferred stocks for income issuers like banks and insurance companies. However, extra income can be achieved by carefully selecting which preferreds from which issuer to in...
fcafotodigital/iStock via Getty Images Introduction AGNC Investment Corp. ( AGNC ) is a Mortgage REIT that offers numerous preferred stocks for income-seeking investors to choose from. These are normally viewed as riskier than preferred stocks for income issuers like banks and insurance companies. However, extra income can be achieved by carefully selecting which preferreds from which issuer to include in their portfolio. Features to consider are covered in the portfolio strategy conclusion of this article. After a brief analysis of AGNC Investment, these preferred stocks will be compared: AGNCL AGNC Investment Corp. Dep Shares Ser G Reset Rate Cumul Preferred Stock AGNCM AGNC Investment Corp., 6.875% Dep Shares Ser D Fix/Float Cumul Red Preferred Stk AGNCN AGNC Investment Corp., 7.00% Dep Shares Ser C Fix/Float Cumul Red Preferred Stk AGNCO AGNC Investment Corp., 6.50% Dep Shares Ser E Fix/Float Cumul Red Preferred Stk AGNCP AGNC Investment Corp. 6.125% Dep Shares Ser F Fix/Float Cumul Red Preferred Stk AGNCZ AGNC Investment Corp. 8.75% Series H Cumulative Preferred Stock Click to enlarge After comparing features, the ratings divide out as: AGNCP and AGNCZ are Buys; AGNCM, AGNCN, and AGNCO are Holds; and AGNCL is a Strong Sell. AGNC Investment Corp. Review Data by YCharts Seeking Alpha describes this mREIT as: AGNC Investment Corp. provides private capital to housing market in the United States. It invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal or state corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as American Capital Agency Corp. and changed its name...
FinkAvenue/iStock Editorial via Getty Images There's a famous story of a man who owns a home, and every day his neighbor yells at him the price that he's willing to pay to buy that house from him. Some days the price is higher, some days the price is lower. But all along, the homeowner refuses to sell because he enjoys the benefits of the home he's in and because he knows the value of the home, in...
FinkAvenue/iStock Editorial via Getty Images There's a famous story of a man who owns a home, and every day his neighbor yells at him the price that he's willing to pay to buy that house from him. Some days the price is higher, some days the price is lower. But all along, the homeowner refuses to sell because he enjoys the benefits of the home he's in and because he knows the value of the home, in his opinion. When it comes to companies trading in the stock market, the overwhelming guiding path they travel along is determined by earnings growth. If a company's earnings continue to grow, then the share value will climb over time, and if the company's earnings decline, then the share value will likely do so as well. However, the stock market is never orderly. In the short term, the stock market is governed by human emotions, fear, and whatever is coming across the news cycle, which can cause prices to be inefficient compared to what the earnings of the company are doing. So what happens when you have a company that is of extreme quality whose share price has struggled and yet continues to see strong earnings growth? Like that homeowner who refuses to sell, you must be able to look past the chaos of the market and look at the clear, data-driven fundamentals of the company. Over the long term, fundamentals always win against market sentiment. In the short term, you may end up on a little bit of a wild ride, but in the long term, you will benefit from buying high-quality companies that see strong earnings growth. Today, I want to take a look at a company that has had a relatively terrible 2026 as far as its market price and yet continues to show extremely strong fundamental health and earnings growth. There continues to be a widening disparity between what the market thinks the company is worth and what the fundamental value of the company is. At the end of the day, fundamentals always win. Let's dive in! The Cash Flow Machine Keeps Printing Visa ( V ) is one of the most...
US Cloud, the world's only independent provider of third-party Microsoft support capable of replacing Microsoft Unified Support, today announced the launch of its new White Label Support Program. This is an industry-first offering designed to help Microsoft partners preemptively respond to major upcoming changes in Microsoft's support ecosystem.
US Cloud, the world's only independent provider of third-party Microsoft support capable of replacing Microsoft Unified Support, today announced the launch of its new White Label Support Program. This is an industry-first offering designed to help Microsoft partners preemptively respond to major upcoming changes in Microsoft's support ecosystem.
Oracle today announced that the Oracle Java SE Universal Subscription will help standardize global software development at Samsung Electronics, a world leader in advanced semiconductor technology. With the Oracle Java SE Universal Subscription, Samsung can simplify IT operations and strengthen security by consolidating its global internal application development on Oracle Java.
Oracle today announced that the Oracle Java SE Universal Subscription will help standardize global software development at Samsung Electronics, a world leader in advanced semiconductor technology. With the Oracle Java SE Universal Subscription, Samsung can simplify IT operations and strengthen security by consolidating its global internal application development on Oracle Java.
If one thing is consistent about the Trump administration, it is its unpredictability. After years of criticizing the current Federal Reserve chairman, Jerome Powell, for his arguably restrictive monetary policy, President Donald Trump has nominated someone who might be more hawkish than his predecessor. Let's dig deeper into Kevin Warsh's track record and past remarks to decide how his term might...
If one thing is consistent about the Trump administration, it is its unpredictability. After years of criticizing the current Federal Reserve chairman, Jerome Powell, for his arguably restrictive monetary policy, President Donald Trump has nominated someone who might be more hawkish than his predecessor. Let's dig deeper into Kevin Warsh's track record and past remarks to decide how his term might affect stock performance. Although the Federal Reserve is independent of the White House, the president can influence its policy orientation by nominating its chairman every four years, subject to Senate confirmation. Trump nominated the current Fed chair, Jerome Powell, in 2017 (he was reappointed by Biden in 2021). And Trump has nominated his successor, Kevin Warsh, with Senate confirmation widely expected on May 15. Image source: Getty Images. Continue reading
ATLANTA, May 12, 2026--Veteran automotive and media executive joins leadership team to accelerate growth and expand Active Shopper Network® capabilities.
ATLANTA, May 12, 2026--Veteran automotive and media executive joins leadership team to accelerate growth and expand Active Shopper Network® capabilities.
Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.
Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.
AlessandroPhoto/iStock via Getty Images Topline Summary and Update When I last took a look at Immuneering Corporation ( IMRX ), I remained an interested skeptic in the overall investment thesis, given the market's enthusiasm for a clinical catalyst that I felt was not really justifying the momentum. The days were too early, and that was months before revolutionary breakthroughs in the space of RAS...
AlessandroPhoto/iStock via Getty Images Topline Summary and Update When I last took a look at Immuneering Corporation ( IMRX ), I remained an interested skeptic in the overall investment thesis, given the market's enthusiasm for a clinical catalyst that I felt was not really justifying the momentum. The days were too early, and that was months before revolutionary breakthroughs in the space of RAS targeting, which is where IMRX plays. Today, I want to digest the updates since then, considering the market's strong negative reaction to a key pancreatic cancer update, and share my thoughts on why IMRX is starting to reach a point where buy-in makes sense. Pipeline Updates Atebimetinib Background The main pipeline candidate continuing to be developed by IMRX is the MEK inhibitor atebimetinib. As a reminder, MEK, is a critical signaling node in the RAS-MAP kinase signaling pathway that tells cells when to grow and proliferate based on the kinds of growth factors they're being exposed to. In cancer, MEK has been an important target in a select few solid tumors, notably melanoma and colon cancer harboring mutations in BRAF. KRAS signaling is critically important in most, if not almost all, pancreatic cancers, where mutations drive a burst of "mitogenic" signaling and lead to worse outcomes. Since MEK is "downstream" of KRAS in the signaling pathway, attacking it should be a viable path to killing the tumor, but this has not panned out with other MEK inhibitors due to rapid development of resistance and toxicity. Atebimetinib has a very short half-life, which IMRX hopes will provide a sort-of pulsatile, rather than continuous, inhibition of MEK. This is hoped to both reduce the toxicity of the drug while also not encouraging the cell to develop resistance so quickly, since the evolutionary pressure isn't so strong. What does that mean for the layman? Essentially, you attack the tumor some, but not so much that you force it to adapt. And in this way you could bring in other ...
In this article .NDX BABA Follow your favorite stocks CREATE FREE ACCOUNT A trader works on the floor of the New York Stock Exchange (NYSE) during the opening bell in New York, on May 11, 2026. Angela Weiss | Afp | Getty Images It's official: traders haven't been this aggressively bullish since they were stuck at home with stimulus checks betting on a bounce-back in the global economy. Retail trad...
In this article .NDX BABA Follow your favorite stocks CREATE FREE ACCOUNT A trader works on the floor of the New York Stock Exchange (NYSE) during the opening bell in New York, on May 11, 2026. Angela Weiss | Afp | Getty Images It's official: traders haven't been this aggressively bullish since they were stuck at home with stimulus checks betting on a bounce-back in the global economy. Retail traders are buying calls in Cboe's "Mag 10" stocks – the big seven plus AMD , Palantir and Broadcom – at the heaviest 10-day clip since 2021, according to a report from the exchange. Of new positions opened, 52% were call-buying, and 17% were call–selling. "Hedgers have thrown in the towel," Mandy Xu, head of derivatives market intelligence for Cboe, said in a call. "It's a consistent theme we're seeing, with people trying to catch up to the market rally through buying calls." It's a sharp about-face from just a month ago when Cboe's call-buying metric was 15 points lower and investors were preoccupied by geopolitics and crude oil prices. The pick-up in optimism matches other data characterizing speculative appetite amid this year's extraordinary surge in tech stocks. The price of call contracts on the Nasdaq-100 index that are one standard deviation out of the money is at a 52-week high and close to a three-year record, according to Nations Indexes' 30-day CallDex Index. "The story is not just that Nasdaq-100 calls are pricey, but that nobody seems interested in selling covered calls," said Nations Indexes president Scott Nations. "That signals a whole other level of bullishness." The Nasdaq-100 set a new record Monday, bringing its year-to-date gain to more than 16%, as semiconductors extend their blistering run and are nearing 20% of the S&P 500's market capitalization. Stock Chart Icon Stock chart icon Nasdaq-100 index, YTD The concentration of the market rally means options traders are placing more bets on single stocks than indexes, keeping volatility elevated on a single...
CBD Life Sciences ( CBDL ) on Tuesday said it will launch a new line of nicotine-free CBD flavored vapes within the next two weeks as the company looks to expand in the fast-growing cannabinoid products market. The Scottsdale, Arizona-based company said the vape lineup will include Menthol, Berry, Tropical, and Mint flavors. CEO Lisa Nelson said CBD vapes represent a major growth opportunity for t...
CBD Life Sciences ( CBDL ) on Tuesday said it will launch a new line of nicotine-free CBD flavored vapes within the next two weeks as the company looks to expand in the fast-growing cannabinoid products market. The Scottsdale, Arizona-based company said the vape lineup will include Menthol, Berry, Tropical, and Mint flavors. CEO Lisa Nelson said CBD vapes represent a major growth opportunity for the company as demand for alternative wellness products rises. The company said it expects the launch to strengthen its position in the broader CBD market and support long-term revenue growt More on CBD Life Sciences Inc. Financial information for CBD Life Sciences Inc.
Carl Zeiss Meditec AG press release ( CZMWF ): 1H GAAP EPS of € 0.17. Revenue of € 991M (-5.6% Y/Y). More on Carl Zeiss Meditec AG Carl Zeiss Meditec AG 2026 Q2 - Results - Earnings Call Presentation Carl Zeiss Meditec: Hitting The Bottom Carl Zeiss Meditec: Bad Optics But With 'Buy' Potential Historical earnings data for Carl Zeiss Meditec AG Dividend scorecard for Carl Zeiss Meditec AG
Carl Zeiss Meditec AG press release ( CZMWF ): 1H GAAP EPS of € 0.17. Revenue of € 991M (-5.6% Y/Y). More on Carl Zeiss Meditec AG Carl Zeiss Meditec AG 2026 Q2 - Results - Earnings Call Presentation Carl Zeiss Meditec: Hitting The Bottom Carl Zeiss Meditec: Bad Optics But With 'Buy' Potential Historical earnings data for Carl Zeiss Meditec AG Dividend scorecard for Carl Zeiss Meditec AG